With all the money going to researching a cure for cancer, you’d assume that if there already was, say, an inexpensive drug that has been proven effective with few-to-no side effects, right? Such a drug apparently exists–but because of its age and lack of patent, it may be being withheld from the public, because no one can make a profit off of it. In an initial report by CTV, out of Canada, the drug DCA is being lauded as a super-cheap, cancer-killing agent that could save lives. But, unfortunately, no one wants to touch it, because it doesn’t stand to make any money.
The video itself explains pretty clearly what’s going on with DCA–it’s been shown to be effective in multiple trial runs, but, because the drug itself has been around for some time, it’s not something that a drug company already owns. Which means this little white powder has a steep uphill battle to face before it can actually be administered.
Before the drug, which has experienced a surge of fresh interest thanks to the research of Dr. Evangelos Michelakis in Alberta, can even get close to becoming widely used, it must be subjected to further studies, which cost money and require a lot of time and energy to shop around to universities and other testing facilities. After that phase, to get a drug through all of the hoops that are required to put it on the market, the start-up cost alone can be up to $100 million–which is a lot to invest, when, because the drug can be made for so little, there’s little chance of making much money back.
Could this be a cause that the ultra-wealthy, like Bill Gates Sr. (or Jr., for that matter) might take up in the interest of the public? Or will we continue to throw money at cancer research in hopes of turning up a new, more profitable, more expensive drug that will cost cancer patients and taxpayers millions? Watch this video to decide for yourself.